214 related articles for article (PubMed ID: 1430093)
1. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
2. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
3. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.
Katznelson L; Oppenheim DS; Coughlin JF; Kliman B; Schoenfeld DA; Klibanski A
J Clin Endocrinol Metab; 1992 Nov; 75(5):1318-25. PubMed ID: 1358910
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
Warnet A; Harris AG; Renard E; Martin D; James-Deidier A; Chaumet-Riffaud P
Neurosurgery; 1997 Oct; 41(4):786-95; discussion 796-7. PubMed ID: 9316039
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
7. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
9. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
Chayen SD; Gross D; Makhoul O; Glaser B
Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
[TBL] [Abstract][Full Text] [Related]
10. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
12. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
13. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
14. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
16. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture.
Kwekkeboom DJ; Hofland LJ; van Koetsveld PM; Singh R; van den Berge JH; Lamberts SW
J Clin Endocrinol Metab; 1990 Sep; 71(3):718-24. PubMed ID: 2394776
[TBL] [Abstract][Full Text] [Related]
18. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
19. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
[TBL] [Abstract][Full Text] [Related]
20. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
Colao A; Merola B; Ferone D; Marzullo P; Cerbone G; Longobardi S; Di Somma C; Lombardi G
Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
